Back to Search
Start Over
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis
- Source :
- PR Newswire. February 1, 2024
- Publication Year :
- 2024
-
Abstract
- Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance PARIS, Feb. 1, 2024 /PRNewswire/ -- Vivet Therapeutics ('Vivet'), a clinical stage biotech company [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.781088002